Oncology Central

Proneural–mesenchymal transformation of glioma stem cells: do therapies cause evolution of target in glioblastoma?


Two distinct cancer stem cell subtypes

Diseases arising in the CNS include glioblastoma (GBM), the most prevalent primary brain tumor and one of the most deadly of all diseases. Conventional therapies are, in most cases, unable to completely eradicate tumor cells and rapid post-therapeutic tumor recurrence results in patients’ mortality. Tumor heterogeneity of GBM is well recognized by three clinically relevant subtypes (proneural [PN], mesenchymal [MES] and classic) based on the unbiased clustering of gene signature [1,2]. However, molecular signaling events in cancer stem cells (CSCs), which may be closely associated with individual GBM subtypes, remain poorly understood.

To view restricted content, please:

Leave A Comment